The global clinical decision support systems market is expected to grow from US$ 3,702.8 million in 2022 to US$ 6,689.2 million by 2028; it is estimated to grow at a CAGR of 10.4% from 2022 to 2028.
Big data acts as a standalone factor driving the overall market growth. Moreover, CDSS for evidence-based decision-making in healthcare stands as a lucrative market opportunity for the overall market growth in the near future.
A clinical decision support system (CDSS) encompasses tools that provide patient-related data to healthcare personnel to take informed decisions at the time of care. These tools involve computerized alerts and reminders to healthcare providers and patients, clinical guidelines, condition-specific order sets, patient data reports and summaries, documentation templates, diagnostic support, and contextually relevant reference information. One of the most widely utilized source tools for collecting multidimensional data by aggregating different sources is Informatics for Integrating Biology and Bedside (i2b2) framework. Moreover, i2b2 is one of the seven centers funded by the US National Institute of Health (NIH) Roadmap for Biomedical Computing. The i2b2 tool's role is to offer clinical investigators a service-based software infrastructure capable of integrating clinical records and research data, along with wide range of search terms for querying. For example, drug prescriptions can be represented through their anatomical therapeutic chemical (ATC) drug codes in drug ontology or a subset of laboratory tests from anatomy pathology.
Further, visual analytics methods can be combined with evidence-based and big data-driven approaches to improve clinical performance through CDSS. Drug–drug interactions (DDIs) involving Vitamin K antagonists (VKAs) constitute an important cause of in-hospital morbidity and mortality. Therefore, the adoption of CDSS offers valuable assistance with VKA prescriptions. CDSS can identify and manage DDIs timely through pop-up alerts and improve the quality of decisions on medication prescriptions. Therefore, influx of big data technologies ultimately drives the overall CDSS market growth.
CDSS is designed to promote evidence-based patient care in the healthcare sector. CDSS adoption can be on the rise in the near future if it is backed by clinical trials and research that recommend an evidence-based medicine approach. Currently, the perception of many clinicians continues to focus on opinion-based medicine rather than evidence-based medicine. With CDSS being widely adopted and accepted, a cultural and behavioral shift at the hospital level can be experienced shortly. Therefore, the adoption of CDSS is critical for medical communities to make the best use of the CDSS system for gaining access to relevant, reliable, and effective clinical guidelines and improving clinical efficacies. For example, the outbreak of COVID-19 accelerated the demand for accurate and evidence-based healthcare information, thereby shortening the timescale of the development of data related to clinical trials. Such evidence-based clinical efficiency will fuel the overall market growth in the near future.
Regional Overview
North America accounts the largest share of the clinical decision support systems market, with the US being the major contributor to the regional market growth. Regulatory mandates favoring the implementation of CDSS and the presence of top competitive players in the region are the most influencing factors for the North American market to grow exponentially during the analysis period. The Office of the National Coordinator for Health IT (ONC) supports efforts to develop, adopt, implement, and evaluate the use of CDSS for improving health and decision-making. The main aim of ONC is to create a technical infrastructure that would allow health systems to share data electronically and offer complete information to the CDSS. The records help CDSS diagnose and track negative drug interactions. Further, innovative product launches by top players are further catalyzing the overall market growth. In December 2021, Change Healthcare announced the launch of "InterQual" in partnership with the American Society of Addiction Medicine (ASAM) to seamlessly integrate with the existing care management workflows to significantly reduce the time required for substance use disorder (SUD) patient assessment, increase consistency, and streamline the prior authorization process using industry standard criteria. Thus, the aforementioned factors are likely to propel the market growth during the forecast period.
Strategic Insights
Component-Based Insights
Based on component, the clinical decision support systems market is segmented into software, hardware, and services. The software segment held the largest market share in 2022. A clinical decision support system is a software tool designed to provide clinicians with relevant medical information that facilitates decision-making or improves adherence to recommended care. For example, CDSS assists a clinician by presenting a patient's medical history and known allergies to the current symptoms in real time, along with a list of potential diagnosis. With software assistance, CDSS can also display an alert directing the nurse to administer medication in a different dosage due to changes in the patient's condition due to allergies. Additionally, CDSS are efficient at translating symptoms into a diagnosis. Once a CDSS tool is integrated with a well-designed emergency medical record (EMR)/emergency health record (EHR), the software can access patient data and process it to suggest a range of possible diagnoses. Such lucrative benefits offered by software on incorporating into a CDSS system provide remarkable segmental growth.
Clinical Decision Support Systems Market, by Component – 2022 and 2028
Companies operating in the clinical decision support systems market adopt product innovation strategy to meet the evolving demands across the world, which also permits them to maintain their brand name in the market.
Clinical Decision Support Systems Market – Segmentation
Based on component, the clinical decision support systems market is segmented into software, hardware, and services. The software segment held the largest market share in 2022. Based on delivery mode, the clinical decision support systems market is segregated into on-premise, cloud-based, and web-based. The on-premise segment held the largest share of the market in 2022. By application, the clinical decision support systems market is segmented into drug–drug interaction, drug allergy alerts, clinical reminders, clinical guidelines, and others. The drug allergy alerts segment held the largest share of the market in 2022. Based on geography, the market is primarily segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.
Company Profiles
- Cerner Corporation
- Medical Information Technology, Inc.
- BD
- Wolters Kluwer N.V.
- Baxter International Inc.
- Premier
- Koninklijke Philips N.V.
- RELX (Elsevier)
- PeraHealth
- Epic Systems Corporation